Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.

Provencio M, Nadal E, Insa A, García Campelo R, Casal J, Dómine M, Massuti B, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro J, Gómez de Antonio D, Macia I, Figueroa S, Fernández Vago L, Calvo V, Palmero R, Sierra-Rodero B, Martínez-Toledo C, Molina-Alejandre M, Serna-Blasco R, Romero A, Cruz-Bermúdez A

Open source

DOI
10.1016/s1470-2045(24)00498-4
Published
2024 Nov
Container
The Lancet. Oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-24-00498-4,
  title = {Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.},
  author = {Provencio M and Nadal E and Insa A and García Campelo R and Casal J and Dómine M and Massuti B and Majem M and Rodríguez-Abreu D and Martínez-Martí A and de Castro J and Gómez de Antonio D and Macia I and Figueroa S and Fernández Vago L and Calvo V and Palmero R and Sierra-Rodero B and Martínez-Toledo C and Molina-Alejandre M and Serna-Blasco R and Romero A and Cruz-Bermúdez A},
  year = {2024},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(24)00498-4},
  url = {https://doi.org/10.1016/s1470-2045(24)00498-4}
}

RIS

TY  - JOUR
TI  - Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
AU  - Provencio M
AU  - Nadal E
AU  - Insa A
AU  - García Campelo R
AU  - Casal J
AU  - Dómine M
AU  - Massuti B
AU  - Majem M
AU  - Rodríguez-Abreu D
AU  - Martínez-Martí A
AU  - de Castro J
AU  - Gómez de Antonio D
AU  - Macia I
AU  - Figueroa S
AU  - Fernández Vago L
AU  - Calvo V
AU  - Palmero R
AU  - Sierra-Rodero B
AU  - Martínez-Toledo C
AU  - Molina-Alejandre M
AU  - Serna-Blasco R
AU  - Romero A
AU  - Cruz-Bermúdez A
PY  - 2024
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(24)00498-4
UR  - https://doi.org/10.1016/s1470-2045(24)00498-4
ER  - 

APA

M, P., E, N., A, I., R, G. C., J, C., M, D., B, M., M, M., D, R., A, M., J, D. C., D, G. D. A., I, M., S, F., L, F. V., V, C., R, P., B, S., C, M., M, M., R, S., A, R., & A, C. (2024). Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(24)00498-4

Source records